Basic mechanisms of the new antiarrhythmic drugs in atrial fibrillation;Principios básicos de las nuevas estrategias farmacológicas antiarrítmicas en fibrilación auricular

Archivos de Cardiologia de Mexico

Volumn 82, Issue 2, 2012, Pages 139-152

  Filgueiras Rama, David ^a,b   Castrejón, Sergio ^a   Calvo, Conrado ^b   Estrada, Alejandro ^a   Doiny, David ^a   Ortega, Marta ^a   Berenfeld, Omer ^b   Merino, José L ^a   Jalife, José ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Antiarrhythmic drugs; Atrial fibrillation; Atrial remodeling; Dronedarone; Ion currents; Rotors; Spain

Indexed keywords

ANTIARRHYTHMIC AGENT;

DRUG MECHANISM; HEART ATRIUM FIBRILLATION; REVIEW; ATRIAL FIBRILLATION; DRUG EFFECTS; ELECTROPHYSIOLOGY; HEART; HUMAN; PHYSIOLOGY;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTROPHYSIOLOGICAL PROCESSES; HEART; HUMANS;

EID: 84865808712     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.
3. Merino JL, Doiny D, Estrada A, et al. Repercusión de la fibrilación auricular: Epidemiología e impacto clínicoeconómico. RIA 2011;1:246-258.
4. Marquez MF, Gomez-Flores J, Aranda-Faustro A, et al. Recientes avances en la fisiopatología de la fibrilación auricular. Arch Cardiol Mex 2009;79 Suppl 2:18-25.
5. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. Antiarr-hythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006;166:719-28.
6. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-2687.
7. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-1968.
8. Morillo CA, Klein GJ, Jones DL, et al. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 1995;91:1588-1595.
9. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J 1959;58:59-70.
10. Moe GK, Rheinboldt WC, Abildskov JA. A Computer Model of Atrial Fibrillation. Am Heart J 1964;67:200-220.
11. Jalife J. ¿Por qué es la Aurícula Izquierda tan Importante en el Mecanismo de la Fibrilación Auricular Crónica? RIA 2009;1:3-26.
12. Kalifa J, Jalife J, Zaitsev AV, et al. Intraatrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 2003;108:668-671.
13. David Filgueiras Rama, José Jalife. Mechanisms Underlying Atrial Fibrillation. In: Charles Antzelevitch, ed. Basic Science for Clinical Electrophysiologist. Philadelphia, USA. Saunders. 2011. 141-156.
14. Yamazaki M, Vaquero LM, Hou L, et al. Mechanisms of stretch-induced atrial fibrillation in the presence and the absence of adrenocholinergic stimulation: interplay between rotors and focal discharges. Heart Rhythm 2009;6:1009-1017.
15. Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of trachycardia. Circ Res 1973;33:54-62.
16. Klos M, Calvo D, Yamazaki M, et al. Atrial septopulmonary bundle of the posterior left atrium provides a substrate for atrial fibrillation initiation in a model of vagally mediated pulmonary vein tachycardia of the structurally normal heart. CircArrhythmElectrophysiol 2008;1:175-183.
17. Cabo C, Pertsov AM, Davidenko JM, et al. Vortex shedding as a precursor of turbulent electrical activity in cardiac muscle. Biophys J 1996;70:1105-1111.
18. Wellner M, Berenfeld O, Jalife J, et al. Minimal principle for rotor filaments. Proc Natl Acad Sci U S A 2002;99:8015-8018.
19. Atienza F, Almendral J, Moreno J, et al. Activation of inward rectifier potassium channels accelerates atrial fibrillation in humans: evidence for a reentrant mechanism. Circulation 2006;114:2434-2442.
20. Berenfeld O, Mandapati R, Dixit S, et al. Spatially distributed dominant excitation frequencies reveal hidden organization in atrial fibrillation in the Langendorff-perfused sheep heart. J Cardiovasc Electrophysiol 2000;11:869-879.
21. Kalifa J, Tanaka K, Zaitsev AV, et al. Mechanisms of wave fractionation at boundaries of high-frequency excitation in the posterior left atrium of the isolated sheep heart during atrial fibrillation. Circulation 2006;113:626-633.
22. Jalife J, Pandit SV. Ionic mechanisms of wavebreak in fibrillation. Heart Rhythm 2005;2:660-663.
23. Kneller J, Kalifa J, Zou R, et al. Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionicallyrealistic mathematical model. Circ Res 2005;96:e35-47.
24. Donovan KD, Power BM, Hockings BE, et al. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol 1995;75:693-697.
25. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989;321:406-412.
26. Antzelevitch C, Burashnikov A, Sicouri S, et al. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heartrhythm 2011;8:1281-1290.
27. Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J CardiovascElectrophysiol 2005;16:1227-1238.
28. Samie FH, Berenfeld O, Anumonwo J, et al. Rectification of the background potassium current: a determinant of rotor dynamics in ventricular fibrillation. Circ Res 2001;89:1216-1223.
29. Noujaim SF, Pandit SV, Berenfeld O, et al. Up-regulation of the inward rectifier K+ current (I K1) in the mouse heart accelerates and stabilizes rotors. J Physiol 2007;578:315-326.
30. Pandit SV, Zlochiver S, Filgueiras-Rama D, et al. Targeting atrioventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs. Cardiovasc Res 2011;89:843-851.
31. Noujaim SF, Stuckey JA, Ponce-Balbuena D, et al. Specific residues of the cytoplasmic domains of cardiac inward rectifier potassium channels are effective antifibrillatory targets. FASEB J 2010;24:4302-4312.
32. Xia M, Jin Q, Bendahhou S, et al. A Kir2.1 gain-of-function mutation underlies familial atrial fibrillation. Biochem Biophys Res Commun 2005;332:1012-1019.
33. Noujaim SF, Stuckey JA, Ponce-Balbuena D, et al. Structural bases for the different antifibrillatory effects of chloroquine and quinidine. Cardiovasc Res 2011;89:862-869.
34. Burrell ZL, Jr., Martinez AC. Chloroquine and hydroxychloroquine in the treatment of cardiac arrhythmias. N Engl J Med 1958;258:798-800.
35. Wang Z, Yue L, White M, et al. Differential distribution of inward rectifier potassium channel transcripts in human atrium versus ventricle. Circulation 1998;98:2422-2428.
36. Berenfeld O. Ionic and substrate mechanism of atrial fibrillation: rotors and the exitacion frequency approach. Arch Cardiol Mex 2010;80:301-314.
37. Voigt N, Trausch A, Knaut M, et al. Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. CircArrhythmElectrophysiol 2010;3:472-480.
38. Ehrlich JR. Inward rectifier potassium currents as a target for atrial fibrillation therapy. J Cardiovasc Pharmacol 2008;52:129-135.
39. Cha TJ, Ehrlich JR, Chartier D, et al. Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation 2006;113:1730-1737.
40. Dobrev D, Friedrich A, Voigt N, et al. The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. Circulation 2005;112:3697-3706.
41. Jin W, Lu Z. A novel high-affinity inhibitor for inward-rectifier K+ channels. Biochemistry 1998;37:13291-13299.
42. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov 2006;5:1034-1049.
43. Patel C, Yan GX, Kowey PR. Dronedarone. Circulation 2009;120:636-644.
44. Inomata N, Ishihara T, Akaike N. Mechanisms of the anticholinergic effect of SUN 1165 in comparison with flecainide, disopyramide and quinidine in single atrial myocytes isolated from guinea-pig. Br J Pharmacol 1991;104:1007-1011.
45. Balana B, Dobrev D, Wettwer E, et al. Decreased ATP-sensitive K(+) current density during chronic human atrial fibrillation. JMCC 2003;35:1399-1405.
46. Samie FH, Mandapati R, Gray RA, et al. A mechanism of transition from ventricular fibrillation to tachycardia: effect of calcium channel blockade on the dynamics of rotating waves. Circ Res 2000;86:684-691.
47. Bollmann A, Sonne K, Esperer HD, et al. Patients with persistent atrial fibrillation taking oral verapamil exhibit a lower atrial frequency on the ECG. Ann Noninvasive Electrocardiol 2002;7:92-97.
48. Pandit SV, Berenfeld O, Anumonwo JM, et al. Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. Biophys J2005;88:3806-3821.
49. Munoz V, Grzeda KR, Desplantez T, et al. Adenoviral expression of IKs contributes to wavebreak and fibrillatory conduction in neonatal rat ventricular cardiomyocyte monolayers. Circ Res 2007;101:475-483.
50. Hou L, Deo M, Furspan P, et al. A major role for HERG in determining frequency of reentry in neonatal rat ventricular myocyte monolayer. Circ Res 2010;107:1503-1511.
51. Ehrlich JR, Nattel S. Novel approaches for pharmacological management of atrial fibrillation. Drugs 2009;69:757-774.
52. Blaauw Y, Gogelein H, Tieleman RG, et al. "Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004;110:1717-1724.
53. Olson TM, Alekseev AE, Liu XK, et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 2006;15:2185-2191.
54. Yehia AR, Shrier A, Lo KC, et al. Transient outward current con-tributes to Wenckebach-like rhythms in isolated rabbit ventricular cells. Am J Physiol 1997;273:H1-11.
55. Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifi-brillatory agent. ExpertOpinInvestigDrugs 2007;16:519-532.
56. Stiell IG, Roos JS, Kavanagh KM, et al. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J 2010;159:1095-1101.
57. Sossalla S, Kallmeyer B, Wagner S, et al. Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol 2010;55:2330-2342.
58. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electro-physiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904-910.
59. Undrovinas AI, Belardinelli L, Undrovinas NA, et al. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J CardiovascElectrophysiol 2006;17 Suppl 1:S169-S77.
60. Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007;116:1449-1457.
61. Fredj S, Sampson KJ, Liu H, et al. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol 2006;148:16-24.
62. Rajamani S, Shryock JC, Belardinelli L. Rapid kinetic interactions of ranolazine with HERG K+ current. J CardiovascPharmacol 2008;51:581-589.
63. Colin Lizalde LJ, Febles Palenzuela T, Crespo Mancebo F, et al. Un estudio retrospectivo para el análisis de los efectos colaterales de la amiodarona. Inst Cardiol Mex 1990;60:455-460.
64. Burashnikov A, Belardinelli L, Antzelevitch C. Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. Heartrhythm 2010;7:1273-1279.
65. Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardio-vascElectrophysiol 2010;21:597-605.
66. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-2687.
67. Joghetaei N, Weirich G, Huber W, et al. Acute liver failure associated with dronedarone. CircArrhythmElectrophysiol 2011;4:592-593.
68. Arya A, Silberbauer J, Teichman SL, et al. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Euro-pace 2009;11:458-464.
69. Gautier P, Serre M, Cosnier-Pucheu S, et al. In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias. J CardiovascPharmacol 2005;45:125-135.
70. Dobrev D, Nattel S. Calcium handling abnormalities in atrial fibrillation as a target for innovative therapeutics. J CardiovascPharmacol 2008;52:293-299.
71. Vest JA, Wehrens XH, Reiken SR, et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 2005;111:2025-2032.
72. Sood S, Chelu MG, van Oort RJ, et al. Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation. Heartrhythm 2008;5:1047-1054.
73. Kumagai K, Nakashima H, Gondo N, et al. Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. J CardiovascElec-trophysiol 2003;14:880-884.
74. Chaldoupi SM, Loh P, Hauer RN, et al. The role of connexin40 in atrial fibrillation. Cardiovasc Res 2009;84:15-23.
75. Shiroshita-Takeshita A, Sakabe M, Haugan K, et al. Model-de-pendent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation 2007;115:310-318.
76. Laurent G, Leong-Poi H, Mangat I, et al. Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs. CircA-rrhythmElectrophysiol 2009;2:171-178.
77. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. CircArrhythmElectrophysiol 2008;1:62-73.
78. Zlochiver S, Munoz V, Vikstrom KL, et al. Electrotonic myofibroblast-to-myocyte coupling increases propensity to reentrant arrhythmias in two-dimensional cardiac monolayers. Biophys J 2008;95:4469-4480.
79. Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am CollCardiol 2003;41:2197-2204.
80. Shinagawa K, Mitamura H, Ogawa S, et al. Effects of inhibiting Na(+)/H(+)-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. Cardiovasc Res 2002;54:438-446.
81. Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606-1617.
82. Anne W, Willems R, Holemans P, et al.Self-terminating AF depends on electrical remodeling while persistent AF depends on additional structural changes in a rapid atrially paced sheep model. J Mol CellCardiol 2007;43:148-158.
83. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am CollCardiol 2005;45:1832-1839.
84. Williams RS, deLemos JA, Dimas V, et al. Effect of spironolactone on patients with atrial fibrillation and structural heart disease. Clin Cardiol 2011;34:415-419.
85. Sakata Y, Chancey AL, Divakaran VG, et al. Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. Basic Res Cardiol 2008;103:60-68.
86. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988.